Study findings support the recent FDA approval of the immunotherapy agent for patients whose cancers have high number of mutations.
The “litmus test” screening methods provide reliable and inexpensive alternatives in patient care settings.
A phase 3 clinical trial finds an anti-inflammatory drug used in rheumatoid arthritis can preserve lung function in patients with systemic sclerosis.
Inhibiting IRE1α, a molecule activated by the endoplasmic reticulum in neutrophils, counters disease progression in lupus mice.
Scientists have long sought to target the interaction between the proteins p53 and Mdm2 in tumor cells, but their interaction in immune cells may be just as important.
The new approach blocks the interaction between cancer cells and immune receptors, showing promise in mice.